(S1A) The effects of inhibitors on SIRT1 T530 phosphorylation. HCT116 cells were exposed to the indicated doses of the pan-DYRK inhibitor harmine, the DYRK3 inhibitor CGP57380, the DYRK1A inhibitor EGCG and the JNK1 inhibitor SP600125 for the indicated times and doses. The extent of inhibition was calculated as the ratio between T530-pSIRT1 and overall SIRT1 detected with an N-terminal SIRT1 antibody. Similar results suggesting inhibition of T530-pSIRT1 specific phosphorylation by harmine were obtained with an immunofluorescence based assay (data not shown). (S1B) The cdk1 inhibitor RO-3306 did not affect T530-pSIRT1 phosphorylation levels for 3 hours. (S1C) Dose responses of T530-pSIRT1 phosphorylation levels after exposure to harmine or SP600125. (S1D) Depletion of DYRK1A did not affect T530-pSIRT1 phosphorylation. ChIP-Seq peaks for T530 pSIRT1, T530A SIRT1 and T530E SIRT1 (colored circles). Origins associated (black numbers) to, and non associated (blue numbers) to either T530 pSIRT1, T530A SIRT1 and T530E SIRT1 are presented as percentage of total origins. Bottom, tables regrouping peak numbers and intersection results for ChIP-Seq (left) and NS-Seq (right).
KO=T530 SIRT1 depleted cells. (B) Overlap between HCT116 nascent strand peaks and
ChIP-Seq peaks for T530-pSIRT1, S139-pMCM2 and H4K16Ac. The raw data and intersection results are listed in supplemental table 2. (C) ChIP-seq with antibodies against T530-pSIRT1 and S139-pMCM2 in cell cycle fractionated K562 cells was compared with nascent strand peaks derived from logarithmically growing K562. Data for these comparisons are shown in supplemental table 3. 
